Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ALT Altimmune, Inc. daily Stock Chart
ALT [NASD]
Altimmune, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.53 Insider Own13.00% Shs Outstand15.11M Perf Week64.10%
Market Cap109.86M Forward P/E- EPS next Y-1.92 Insider Trans-10.18% Shs Float12.90M Perf Month156.01%
Income-22.30M PEG- EPS next Q-0.52 Inst Own10.60% Short Float12.65% Perf Quarter378.70%
Sales5.10M P/S21.54 EPS this Y89.50% Inst Trans28.93% Short Ratio0.51 Perf Half Y399.38%
Book/sh2.77 P/B2.92 EPS next Y7.80% ROA-39.40% Target Price- Perf Year216.02%
Cash/sh2.42 P/C3.34 EPS next 5Y- ROE-46.20% 52W Range1.51 - 10.68 Perf YTD328.04%
Dividend- P/FCF- EPS past 5Y50.20% ROI-47.00% 52W High-24.25% Beta0.91
Dividend %- Quick Ratio6.60 Sales past 5Y-10.70% Gross Margin- 52W Low435.76% ATR0.88
Employees25 Current Ratio6.60 Sales Q/Q-26.70% Oper. Margin- RSI (14)88.70 Volatility27.74% 14.14%
OptionableYes Debt/Eq0.00 EPS Q/Q4.30% Profit Margin- Rel Volume2.17 Prev Close8.09
ShortableYes LT Debt/Eq0.00 EarningsMay 14 BMO Payout- Avg Volume3.17M Price8.09
Recom- SMA2080.48% SMA50120.28% SMA200234.32% Volume0 Change0.00%
Feb-24-20Resumed ROTH Capital Buy $13
Jul-19-19Initiated ROTH Capital Buy $8.30
Oct-09-17Initiated Piper Jaffray Overweight $6
May-15-20 08:58AM  Is the Options Market Predicting a Spike in Altimmune (ALT) Stock? Zacks
May-13-20 05:18PM  Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update GlobeNewswire +11.62%
05:18PM  Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update Globenewswire Test
09:15AM  Stocks Slide About 2%, Ending NASDAQ's Six-Day Run Zacks
May-12-20 07:00AM  Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors GlobeNewswire +17.46%
May-09-20 08:11AM  Introducing Altimmune (NASDAQ:ALT), The Stock That Collapsed 98% Simply Wall St.
May-08-20 07:00AM  Altimmune to Announce First Quarter 2020 Financial Results on May 14 GlobeNewswire
May-06-20 02:50PM  These 23 companies are working on coronavirus treatments or vaccines heres where things stand MarketWatch
Apr-20-20 09:01AM  Part of Washington Convention Center to become field hospital for COVID-19 patients American City Business Journals
Apr-13-20 08:58AM  The Race Continues for a COVID-19 Vaccine; 3 Healthcare Stocks to Watch TipRanks
Apr-08-20 09:15AM  Strong Open Tumbles to Slight Losses in Volatile Session Zacks
Apr-02-20 02:51PM  Exclusive: Rockville bio raising $50M, building COVID-19 vaccine and plotting IPO American City Business Journals
Mar-30-20 07:00AM  Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine GlobeNewswire +5.96%
Mar-27-20 07:15AM  Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update GlobeNewswire -12.31%
06:30AM  Altimmune Inc to Host Earnings Call ACCESSWIRE
Mar-25-20 04:30PM  Altimmune to Announce Year End 2019 Financial Results on March 27 GlobeNewswire +7.19%
Feb-28-20 07:00AM  Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine GlobeNewswire +110.23%
Feb-19-20 04:30PM  Altimmune to Present at the Cowen 40th Annual Health Care Conference GlobeNewswire
Feb-04-20 07:00AM  Altimmune to Present at Upcoming Investor and Scientific Conferences GlobeNewswire
Jan-31-20 04:58PM  Penny Stocks to Buy Using Technical Analysis for February 2020 Investopedia
Jan-23-20 07:00AM  Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer GlobeNewswire
Jan-07-20 08:43AM  Altimmune to Present at the 2020 NASH-TAG Conference GlobeNewswire
Dec-23-19 03:59PM  Hedge Funds Have Never Been More Bullish On Altimmune, Inc. (ALT) Insider Monkey
Nov-21-19 08:00AM  Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH GlobeNewswire +7.74%
Nov-13-19 04:15PM  Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Nov-11-19 05:43AM  If You Had Bought Altimmune (NASDAQ:ALT) Stock A Year Ago, You'd Be Sitting On A 48% Loss, Today Simply Wall St.
Nov-06-19 07:00AM  Altimmune to Announce Third Quarter 2019 Financial Results on November 14 GlobeNewswire
Nov-01-19 02:41PM  Why the Facebook political-ads debate could be a windfall for legacy media Barrons.com
Oct-10-19 07:00AM  Altimmune to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-09-19 07:00AM  Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer GlobeNewswire +5.45%
Aug-21-19 07:00AM  Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield Clinical Development GlobeNewswire
Aug-13-19 04:15PM  Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Aug-07-19 11:27AM  Germantown biopharma regains compliance with Nasdaq American City Business Journals
Aug-05-19 07:00AM  Altimmune to Announce Second Quarter 2019 Financial Results on August 14 GlobeNewswire
Jul-15-19 07:00AM  Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc. GlobeNewswire
Jul-12-19 02:55PM  Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business American City Business Journals
Jul-09-19 04:45PM  Altimmune to acquire California company for up to $93M American City Business Journals +6.40%
01:39PM  Germantown stem cell therapy company proposes $7M offering amid delisting threat American City Business Journals
08:48AM  Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio Benzinga
07:15AM  Altimmune's stock soars after adding NASH candidate with purchase of Spitfire Pharma MarketWatch
07:00AM  Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio GlobeNewswire
Jun-12-19 08:00AM  Altimmune Appoints Will Brown as Chief Financial Officer GlobeNewswire
Jun-10-19 08:00AM  Altimmune Announces Successful Pre-IND Meeting with FDA GlobeNewswire
Jun-05-19 08:00AM  Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs GlobeNewswire
May-14-19 04:15PM  Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
May-08-19 08:00AM  Altimmune to Announce First Quarter 2019 Financial Results on May 15 GlobeNewswire
Apr-11-19 09:27AM  Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C. GlobeNewswire
Apr-02-19 06:30AM  Altimmune, Inc. to Host Earnings Call ACCESSWIRE -7.69%
Apr-01-19 04:20PM  Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update GlobeNewswire +12.07%
Mar-21-19 04:15PM  Altimmune to Announce Year End 2018 Financial Results on April 2 GlobeNewswire
Mar-19-19 12:21PM  Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data InvestorPlace +14.88%
08:12AM  Altimmune's stock soars on heavy volume after positive trial data of flu vaccine candidate MarketWatch
07:00AM  Altimmune Announces Positive Results from NasoVAX Extension Study GlobeNewswire
Mar-14-19 09:00AM  Altimmune to Participate at 31st Annual ROTH Conference GlobeNewswire
Mar-12-19 01:34PM  Altimmune Announces Closing of $14 Million Registered Direct Offering GlobeNewswire
Mar-08-19 09:29AM  Altimmune Announces $14 million Registered Direct Offering GlobeNewswire -36.56%
Jan-29-19 08:00AM  Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress in Vienna, Austria GlobeNewswire
Dec-14-18 07:00AM  Today's Research Reports on Trending Tickers: Sage Therapeutics and Altimmune ACCESSWIRE -10.79%
Dec-13-18 07:01AM  Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion GlobeNewswire -20.98%
Nov-30-18 06:06PM  Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +5.59%
Nov-27-18 09:00AM  Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer GlobeNewswire
Nov-23-18 07:00AM  Today's Research Reports on Trending Tickers: Altimmune and Johnson & Johnson ACCESSWIRE
Nov-13-18 04:50PM  Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Oct-26-18 11:29AM  Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference GlobeNewswire
Oct-23-18 03:05PM  Gaithersburg biotech CEO to step down American City Business Journals
Oct-17-18 08:00AM  Todays Research Reports on Stocks to Watch: Altimmune and MannKind ACCESSWIRE
Oct-08-18 12:35PM  Why Altimmune Stock Is Sliding Lower Today InvestorPlace -31.77%
09:00AM  Altimmune Announces $25 million Registered Direct Offering GlobeNewswire
Oct-03-18 08:00AM  Altimmune Closes on $16.9 Million in Funding GlobeNewswire
Oct-01-18 08:00AM  Todays Research Reports on Stocks to Watch: Aytu Bioscience and Altimmune ACCESSWIRE +13.18%
Sep-28-18 09:01AM  Altimmune Announces Pricing of $12 Million Underwritten Public Offering GlobeNewswire -49.89%
Sep-24-18 09:00AM  Altimmune Announces $4.9 million Registered Direct Offering of Common Stock GlobeNewswire -46.93%
08:00AM  Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield Development GlobeNewswire
Sep-20-18 08:00AM  Todays Research Reports on Stocks to Watch: Molecular Templates and Altimmune ACCESSWIRE +59.36%
Sep-19-18 05:16PM  Why Altimmune Stock Is Skyrocketing Today InvestorPlace +285.48%
Sep-04-18 08:00AM  Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine GlobeNewswire
Aug-31-18 08:00AM  Altimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 Study GlobeNewswire
Aug-15-18 06:30AM  Altimmune, Inc. to Host Earnings Call ACCESSWIRE
Aug-14-18 04:01PM  Altimmune Announces Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +9.39%
Aug-07-18 08:00AM  Altimmune to Announce Second Quarter 2018 Financial Results on August 15 GlobeNewswire
Jul-12-18 08:00AM  Altimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors GlobeNewswire
Jul-10-18 08:00AM  Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds José Ochoa to Its Leadership Team as Chief Business Officer GlobeNewswire
Jun-22-18 04:15PM  Altimmune Restructures Financing Agreement GlobeNewswire
Jun-11-18 07:10AM  Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks ACCESSWIRE -14.92%
Jun-05-18 06:45AM  U.S. hedge fund Hudson Bay to open London office - sources Reuters +5.62%
May-24-18 01:47PM  Does Altimmune Incs (NASDAQ:ALT) CEO Salary Reflect Performance? Simply Wall St. -7.77%
May-18-18 04:55PM  Gaithersburg biotech faces threat of stock delisting American City Business Journals
May-15-18 04:01PM  Altimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-08-18 06:03PM  Who Are The Major Shareholders Of Altimmune Inc (NASDAQ:ALT)? Simply Wall St.
08:00AM  Altimmune to Announce First Quarter 2018 Financial Results on May 16 GlobeNewswire
Apr-19-18 07:40AM  Free Research Report as ChemoCentryxs Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y ACCESSWIRE
Mar-28-18 04:44PM  Altimmune Announces Financial Results for the Year Ended December 31, 2017 and Provides Corporate Update GlobeNewswire -13.04%
11:10AM  Heres Whats Moving Esperion And Altimmune, Inc. Market Exclusive
Mar-27-18 08:00AM  Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection GlobeNewswire -17.86%
Mar-22-18 04:01PM  Altimmune to Participate at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-20-18 04:01PM  Altimmune to Announce Year End 2017 Financial Results on March 29 GlobeNewswire
Mar-12-18 04:34PM  Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program GlobeNewswire
Mar-06-18 08:00AM  Altimmune to Participate at Two Investor Conferences in March GlobeNewswire -5.73%
Jan-23-18 08:00AM  Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S. GlobeNewswire
Jan-22-18 08:00AM  Altimmune to Participate at the Noble Capital 14th Annual Investor Conference GlobeNewswire
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VELOCITY PHARMACEUTICAL HOLDIN10% OwnerMay 15Sale4.6530,622142,3921,687,250May 18 04:45 PM
VELOCITY PHARMACEUTICAL HOLDIN10% OwnerMay 14Sale4.81169,378814,7081,717,872May 18 04:45 PM
Garg Vipin KPresident and CEOSep 05Buy2.1020,00042,000342,907Sep 05 05:04 PM
open in yahoo | open in reuters | open in google